You are leaving Evergreentgn.com
You have clicked on an external link and will be taken offsite.
Cancel
Confirm

News

view details
January 28, 2025

Lantheus to Acquire Evergreen Theragnostics for Upfront Payment of $250 Million to Drive Strategic Evolution into Fully Integrated Radiopharmaceutical Leader
view details
October 18, 2024

Evergreen Theragnostics opens CCK2-VIEW, a Phase II small cell lung cancer clinical trial, in the European Union
view details
May 28, 2024

Evergreen Theragnostics announces licensing of EVG321 from Medical University of Innsbruck and enters clinical development of Radioligand Therapies in small cell lung cancer
view details
June 8, 2023

CAM-H2 production at Evergreen marks the expansion of Precirix’ clinical trial to the US
view details
April 3, 2023

Orbit Discovery and Evergreen Discovery collaborate to discover peptides for targeting radiopharmaceuticals
view details
August 18, 2022

Clarity and Evergreen expand Targeted Copper Theranostics manufacturing
view details
March 16, 2022

Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
view details
December 1, 2021

MTTI partners with Evergreen to manufacture EvaThera platform of radiopharmaceuticals
view details
October 18, 2021

Evergreen Theragnostics Completes New Jersey Manufacturing Facility